HOME > Investor Relations > Financial Results Highlights > Segment Information

Segment Information

Self-Medication Operation Group

Net sales

Operating income

  1. *The horizontal scale of each graph represents fiscal years ended March 31.

Sales of Main Brands/Sales of Main Brands Composition

(Year ended March 31, 2018) Fractions of 0.1 billion are rounded off

Billions of yen
  Sales % of total
 Lipovitan series 52.0 28.9%
Including
Lipovitan D
33.4 18.5%
 Pabron series 28.9 16.0%
 RiUP series 15.3 8.5%
 Biofermin series 10.2 5.7%
 VICKS series 4.0 2.2%
Gastrointestinal
treatment series
3.7 2.1%
 Livita series 3.4 1.9%
 Colac series 3.0 1.7%
 NARON series 3.0 1.7%
 Overseas 30.9 17.2%
 Others 25.7 14.3%

Self-Medication:Our Business

Prescription Pharmaceutical Operation Group

Net sales

Operating income

  1. *The horizontal scale of each graph represents fiscal years ended March 31.

Sales of Main Products/Sales of Main Products Composition

(Year ended March 31, 2018) Fractions of 0.1 billion are rounded off

Billions of yen
  Sales % of total
 EDIROL 26.2 32.2%
 Bonviva 6.4 7.9%
 ZOSYN 6.1 7.5%
 Lusefi 5.6 6.9%
 Clarith 5.3 6.5%
 Biofermin 3.9 4.8%
 Palux 3.5 4.3%
 Geninax 3.5 4.3%
 LOQOA 3.5 4.3%
 OZEX 2.8 3.4%
 Others 14.6 17.9%

Prescription Pharmaceutical:Our Business